The importance of motion diagnostics to promote early physical activity in children with rheumatic diseases

Not Applicable

Recruiting

• Conditions: M08.0; M08.2; M08.3; M08.4; M08.8; Juvenile rheumatoid arthritis; Juvenile arthritis with systemic onset; Juvenile polyarthritis (seronegative); Pauciarticular juvenile arthritis; Other juvenile arthritis

• Registration Number: DRKS00017272
• Lead Sponsor: Professur für Biomechanik im Sport, Fakultät für Sport- und Gesundheitswissenschaften, Technische Universität München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 125

Inclusion Criteria

T0:
• Diagnosis of a JIA according to ILAR criteria (Petty et al., 2004)
• new disease (shorter than 12 months)
• Pre-treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and cortisone (maximum 0.2 mg / kg body weight prednisolone equivalent) is possible
• Active JIA disease according to Wallace et al., 2004
• Age from 6 to 16 years
• Involvement of the lower and / or upper limb and / or the spine
• German Speaking

T1':
• Diagnosis of a JIA according to ILAR criteria (Petty et al., 2004), inactive state of disease (cJADAS 10: oligo =1.5, polyartikulär =2.5)
• duration of disease at first visit to a pediatric rheumatoligist = 12 months, 6-months intervals of rheumatological screenings after first diagnosis, total duration of disease = 24 months at t1'
• Pre-treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and cortisone (maximum 0.2 mg / kg body weight prednisolone equivalent) is possible
• Age from 6 to 17years
• Involvement of the lower and / or upper limb and / or the spine
• German Speaking

Exclusion Criteria

T0:
• Pre-treatment with Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) > 3 months and Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) > 3 months
• Chronic pain disorder
• Neurological diseases
• abnormalities of cognitive function
• No interest
• Pretreatment with cortisone> 0.2 mg / kg body weight prednisolone equivalent
• Participation in other interventional studies

T1':
• Already participating at t0
• Pre-treatment with Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) > 15 months and Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) > 15 months
• intra-articular injection (<4 weeks ago)
• Chronic pain disorder
• Neurological diseases
• abnormalities of cognitive function
• No interest
• Pretreatment with cortisone> 0.2 mg / kg
• Participation in other interventional studies

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint in this study is the functional improvement of JIA patients with a functional deficit through an optimal sports recommendation. The parameters are collected at the measurement t1/t1' and t2. Changes are quantified with a fitness test (Deutscher Motorik-Test).

Secondary Outcome Measures

Name	Time	Method
The secondary endpoint is a consistent minimal inflammatory activity and pain intensity as well as an improvement in health-related quality of life. The parameters are recorded at t1/t1' and t2 in the clinic. For this purpose, clinical parameters and subjective parameters of a patient survey are used.